|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Stepwise approach and surgery for gallbladder adenomyomatosis: a mini-review显示文摘BACKGROUND: Gallbladder adenomyomatosis (GBA) is a hyperplastic disease affecting the wall of the gallbladder, with some typical features. It has historically been considered a benign condition, nevertheless recent reports highlighted a potential role of GBA in predisposing to malignancies of the gallbladder. DATA SOURCES: We reviewed the literature concerning GBA from its identification until July 2012. Owing to the relative rarity of the disease, studies often are case reports or case series. Thus we herein report a summary of the key-points concerning diagnosis and treatment of GBA, easily applicable in everyday practice, rather than a systematic review. Also, results are integrated with our recent experience. RESULTS: In our experience, we observed a trend toward an increase of GBA during the last years, probably due to enhanced ultrasonographic technical advancements and physician's expertise. GBA has distinctive imaging features. Several recent reports highlight the potential risk of cancer associated with GBA; however the disease is still classified as a benign condition. Although its correlation with malignancy has not been demonstrated, it is prudent to recommend cholecystectomy in some cases. However, in selected asymptomatic patients, a wait-and-see policy is a viable alternative. We propose an algorithm, based on GBA pathological pattern (diffuse, segmental, localized or fundal), suitable for decision-making.CONCLUSIONS: In symptomatic patients and if the diagnosis is doubtful, cholecystectomy is mandatory. Postponing surgery is an option to be offered to asymptomatic patients with low-risk GBA pattern who adhere to scheduled follow-ups. | Gianluca Pellino Guido Sciaudone Giuseppe Candilio Giuseppe Perna Antonio Santoriello Silvestro Canonico Francesco SelvaggiAuthor | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，2： | 9 |
| 2 | Precision medicine in gastric cancer显示文摘Gastric cancer(GC)is a complex disease linked to a series of environmental factors and unhealthy lifestyle habits,and especially to genetic alterations.GC represents the second leading cause of cancer-related deaths worldwide.Its onset is subtle,and the majority of patients are diagnosed once the cancer is already advanced.In recent years,there have been innovations in the management of advanced GC including the introduction of new classifications based on its molecular characteristics.Thanks to new technologies such as next-generation sequencing and microarray,the Cancer Genome Atlas and Asian Cancer Research Group classifications have also paved the way for precision medicine in GC,making it possible to integrate diagnostic and therapeutic methods.Among the objectives of the subdivision of GC into subtypes is to select patients in whom molecular targeted drugs can achieve the best results;many lines of research have been initiated to this end.After phase III clinical trials,trastuzumab,anti-Erb-B2 receptor tyrosine kinase 2(commonly known as ERBB2)and ramucirumab,anti-vascular endothelial growth factor receptor 2(commonly known as VEGFR2)monoclonal antibodies,were approved and introduced into first-and second-line therapies for patients with advanced/metastatic GC.However,the heterogeneity of this neoplasia makes the practical application of such approaches difficult.Unfortunately,scientific progress has not been matched by progress in clinical practice in terms of significant improvements in prognosis.Survival continues to be low in contrast to the reduction in deaths from many common cancers such as colorectal,lung,breast,and prostate cancers.Although several target molecules have been identified on which targeted drugs can act and novel products have been introduced into experimental therapeutic protocols,the overall approach to treating advanced stage GC has not substantially changed.Currently,surgical resection with adjuvant or neoadjuvant radiotherapy and chemotherapy are the most effective treatments for this disease.Future research should not underestimate the heterogeneity of GC when developing diagnostic and therapeutic strategies aimed toward improving patient survival. | Patrizia Bonelli Antonella Borrelli Franca Maria Tuccillo Lucrezia Silvestro Raffaele Palaia Franco Maria Buonaguro | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 8 |
| 3 | 设计待机功耗仅为30mW的手机充电器显示文摘反激式电路结构通常用于低功率适配器的设计。在反激式设计中.市电输入在以高频开关之前将经由隔离变压器进行整流。对于这种设计结构.如果要求超高效率,设计师则会面临以下两大难题。首先,在恒流模式下.必须可以检测到负载电流并将反馈信号传送到初级侧;但是, | Silvestro Fimiani | 2009 | 电子设计技术 EDN CHINA2009，，12： | 2 |
| 4 | 单级功率因数校正LED驱动器显示文摘引言
新的能源之星LED驱动器法规要求家用产品的功率因数(PF)达到0.7或更高,要求商用产品的功率因数(PF)达到0.9。本文将介绍一款适用于LED驱动器的极具成本效益的单级功率因数校正(PFC)电路,采用Power Integrations公司的TOPSwitch-Gx系列产品TOP259YN设计而成。本设计采用单级方法,可降低驱动器成本并提高效率。 | Silvestro Fimiani | 2008 | 电子设计应用2008，，9： | 2 |
| 5 | 充分发挥LED照明的能效优势显示文摘在LED照明产业发展对LED驱动器设计的要求日益提高的背景下,本文提出了可满足应用需求的LED驱动器解决方案LinkSwitch-Ⅱ系列,并对其电路设计中的优越性进行了说明。 | Silvestro Fimiani | 2009 | 电子设计应用2009，，6： | 2 |
| 6 | Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity 显示文摘 | Graziani L Silvestro A Bertone V | 2007 | Eur J Vasc Endovasc Surg2007，33，10： | 1 |
| 7 | A new integrated membrane process for the production of concentrated blood orange juice: effect of methods for must processing and preservation显示文摘 | GALAVERNA Gianni SILVESTRO Gianluca Di CASSANO Alfredo | 2008 | Food Chemistry2008，106，3： | 1 |
| 8 | Sclerosing stromal tumor of the ovary:report of eight cases and review of the literature显示文摘 | Marelli G Silvestro C Mariani A | 1998 | Eur J Obstet Gynecol Reprod Biol1998，76，1： | 1 |
| 9 | Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease显示文摘 | Graziani L Silvestro A Bertone V | 2007 | Nephrol Dial Transplant2007，22，4： | 1 |
| 10 | Targeting thymidylate synthase in colorectal cancer:critical re-evaluation and emerging therapeutic role of raltitrexed显示文摘 | Avallone A Di Gennaro E Silvestro L | 2014 | Expert Opin Drug Saf2014，13，1： | 1 |
| 11 | Vascular Involvement in diabetic subjects with ischemic foot ulcer:a new morphologic categorization of disease severity显示文摘 | Graziani L Silvestro A Beaone V | 2007 | Eur J Vase Endovasc Surg2007，33，： | 1 |
| 12 | Mobilization of peripheral blood hematopoietic stem cells following liver resection surgery 显示文摘 | DE SILVESTRO G VICARIOTO M DONADEL C | 2004 | Hepatogastroenterol2004，51，57： | 1 |
| 13 | The comcentration-dipendent menbrane activity of ceropin A显示文摘 | Silvestro L Gupta K Weiser J N | 1997 | Biochemistry1997，36，38： | 1 |
| 14 | A single institution experience with plasma-exchange therapy in patients with fulminant hepatic failure显示文摘 | De Silvestro G Marson P Brandolese R | 2000 | Int J Artif Organs2000，23，7： | 1 |
| 15 | Vaseular involvement in diabetic subjects with ischemic foot ulcer:a new morphologic categorization of disease severity显示文摘 | Graziani L Silvestro A Bertnne V | 2007 | Eur J V&sc Endovasc Surg2007，33，4： | 1 |
| 16 | Development and application of a high-performance liquid chromatography-mass spectrometry method to determine alendronatein human urine显示文摘 | Isabela Tarcomnicu Luigi Silvestro Simona Rizea Savu | 2007 | Journal of Chromatography A2007，1160，12： | 1 |
| 17 | Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with servere peripheral artery disease 显示文摘 | Graziani L Silvestro A Bertone V | 2007 | Nephrol Dial Tansplant2007，22，4： | 1 |
| 18 | Development and application of a high- performance liquid chromatography- mass spectrometry method to determine alendronate in human urine 显示文摘 | Tareomnicu I Silvestro L Savu SR | 2007 | J Chromatogr A2007，1160，12： | 1 |
| 19 | Vascular involvement in diabetic subjects with ischemic foot ulcer:a new morphologic categorization of disease severity显示文摘 | Graziani L Silvestro A Bertone V | | 0，，： | 1 |
| 20 | Increased inflamma- tory status and higher prevalence of three-vessel coronary ar- tery disease in patients with concomitant coronary and periph- eral atherosclerosis显示文摘 | Brevetti G Piseione F Silvestro A | 2003 | Thromb Haemost2003，89，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员